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Original Article
Gene expression alterations in bipolar disorder
postmortem brains
Bipolar disorder (BD) is a chronic, severe psychi-
atric illness characterized by recurrent pathological
swings of mood between mania and depression,
often with catastrophic social, personal, medical,
or vocational consequences. It is generally a
lifetime diagnosis, with significant heterogeneity,
that begins in late adolescence or early adulthood
with variability in presentation, symptomatology
and course of illness (1). Genetic predisposition to
the illness and high heritability have been observed
clinically in family, twin, and adoption studies (2–4),
and genetic linkage and association studies have
found numerous modest risk loci for BD (5),
consistent with a complex mode of inheritance in
BD (6, 7). The currently reported genetic variants
with modest odds ratios (1.1–1.3) cannot account
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Objectives: Bipolar disorder (BD) is a mental illness of unknown
neuropathology and has several genetic associations. Antipsychotics are
effective for the treatment of acute mania, psychosis, or mixed states in
individuals with BD. We aimed to identify gene transcripts differentially
expressed in postmortem brains from antipsychotics-exposed individuals
with BD (hereafter the exposed group), non-exposed individuals with
BD (hereafter the non-exposed group), and controls.
Methods: We quantified the abundance of gene transcripts in
postmortem brains from seven exposed individuals, seven non-exposed
individuals, and 12 controls with the Affymetrix U133P2 GeneChip
microarrays and technologies. We applied a q-value of £0.005 to identify
statistically significant transcripts with mean abundance differences
between the exposed, non-exposed and control groups.
Results: We identified 2191 unique genes with significantly altered
expression levels in non-exposed brains compared to those in the control
and exposed groups. The expression levels of these genes were not
significantly different between exposed brains and controls, suggesting a
normalization effect of antipsychotics on the expression of these genes.
Gene ontology (GO) enrichment analysis showed significant (Bonferroni
p £ 0.05) clustering of subgroups of the 2191 genes under many GO
terms; notably, the protein products of genes enriched are critical to the
function of synapses, affecting, for example, intracellular trafficking and
synaptic vesicle biogenesis, transport, release and recycling, as well as
organization and stabilization of the node of Ranvier.
Conclusions: These results support a hypothesis of synaptic and
intercellular communication impairment in BD. The apparent
normalization of expression patterns with exposure to antipsychotic
medication may represent a physiological process that relates both to
etiology and improvement patterns of the disorder.
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for the high heritability of the disorder; additional
approaches beyond population genetics will be
needed to understand the etiology of BD.
Gene expression analyses have used microarray
technology to identify gene transcripts differen-
tially expressed in postmortem brains or nucleated
peripheral blood cells from BD affected individuals
in comparison to healthy controls (8–16).
Although these studies have identified sets of genes
differentially expressed between BD samples and
controls (see Supplementary Table 1), only a few
genes within each set replicate in two or more
studies.
A recent meta-analysis of 12 microarray data
sets was performed to address the lack of consen-
sus between studies (17); the results suggested that
inconsistency between microarray studies was due
to small sample size, overly restrictive or overly
broad criteria for assigning of significance, and a
lack of consistent statistical adjustment for con-
founding effects. However, the meta-analysis did
identify 375 genes with significantly altered expres-
sion patterns in BD brains compared with controls.
Many genes identified in this analysis are func-
tionally related to energy processing, supporting an
energy processing dysfunction hypothesis in BD
(10, 17).
Given the complex inheritance of BD and the
current progress in gene mapping and expression
analyses, we reason that findings from each
independent study are likely to contribute to
understanding the molecular basis of the illness.
The integration and comparison of results from
independent studies may prove helpful in the
identification of genes and pathways for prioriti-
zation of deeper analyses. We compared the
abundance of gene transcripts in brain samples
from deceased individuals diagnosed with BD and
unrelated controls, and identified transcripts with
altered expression levels in BD brains (including
many previously reported significant genes). When
we used exposure to antipsychotic medication as a
variable, we found evidence that antipsychotics
normalize the expression levels of genes in BD
brains to near control levels.
Materials and methods
Postmortem brain samples
Postmortem brain samples (hereafter brains) were
obtained from the Stanley Medical Research
Institute (SMRI) neuropathology consortium
(18). All brains were collected using Institutional
Review Board (IRB) approved protocols for
postmortem tissue collection and later provided
to qualified investigators for analysis. The consor-
tium consists of brains from individuals with
BD, schizophrenia and major depression (15 brains
in each case) and from healthy controls (15
brains). All brains were matched by gender, age,
race, postmortem interval (PMI), brain pH, and
the side of the brain from which the sample was
taken, and excluded neuropathological abnormal-
ities. We analyzed the BD (n = 15) and normal
control brains (n = 15) in this study (Tables 1
and 2). The tissue sample was derived from the
premotor cortex (Brodmanns area 6). Due to
poor RNA quality, three samples (two controls
and one BD) were not processed for microarray
GeneChip hybridization. Medication history
indicated that, for half of the 14 BD brains
included in the microarray analysis, the individual
was on antipsychotics at the time of death
(Tables 1 and 2).
RNA extraction
Total RNA was isolated from 200 mg of frozen
tissue using the TRIzol reagent (Cat #15596-026;
Invitrogen, Grand Island, NY, USA). All RNA
samples were then treated with RNase-free DNase
(Cat #79254; Qiagen, Valencia, CA, USA),
followed by a clean-up step with the RNeasy
MinElute Cleanup reagents (Cat #74204; Qiagen)
according to the manufacturers instructions. RNA
quantity was determined using an ND-1000 spec-
trophotometer (NanoDrop Technologies, Inc.,
Wilmington, DE, USA). One microgram of RNA
from each sample was subjected to 1% agarose gel
electrophoresis to examine RNA integrity and
potential DNA contamination. The RNA samples
were stored at )80C until microarray analysis.
Microarray platforms and data acquisition
The GeneChip U133 plus 2.0 (U133P2) micro-
arrays (Affymetrix, Santa Clara, CA, USA) were
used for expression analysis of RNA from post-
mortem brains. Affymetrix microarray hybridiza-
tion was carried out at the Johns Hopkins Medical
School microarray core facilities. Image processing
and scaling for normalization were carried out
using GCOS1.1 software (Affymetrix). Standard
Affymetrix microarray quality controls were em-
ployed, including: scaling factor, noise, back-
ground, percentage of present calls, 5¢ ⁄3¢ signal
ratios observed in the GAPDH messenger RNA
(mRNA), and the 5¢ ⁄3¢ signal ratios of spiking
genes. There were no significant differences
between BD and control groups in the variances
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ratios of GAPDH (data not shown). One brain
sample, coded UK-1.41 (SMRI sample code), had
a 3¢ ⁄5¢ signal ratio of GAPDH 4.64, which was
greater than an adequate threshold of three for
brain tissue (19) and was therefore removed from
the statistical analysis. Data that passed these
quality control measures were then used in differ-
ential expression analyses. Thus, a total of 26
microarray profiles (14 BD and 12 controls) were
included in the statistical analysis of differential
gene expression.
Microarray data analysis
For analysis of the U133P2 microarray data, we
processed raw data (CEL files) using the Biocon-
ductor package Affy for R (20, 21). We used the
Affy Robust Multichip Average (RMA) algorithms
for background adjustment, probe intensity sum-
marization, and normalization. Log2-transformed
probe intensity RMA values were used in differen-
tial gene expression analysis.
We classified the postmortem brains into three
groups (Tables 1 and 2): (i) those from BD patients
who were treated with antipsychotics at the time of
death and during their lifetime (the exposed
group; n = 7); (ii) those from BD patients who
were never treated with antipsychotics (the non-
exposed group; n = 7); and (iii) those from
normal controls (n = 12). This strategy for data
analysis is different from the simple case–control
comparison performed in previously published
studies using the neuropathology consortium sam-
ple from SMRI (see Supplementary Table 1). Other
medications were generally equally distributed
between the two BD groups.
We used the Significant Analysis of Microarrays
(SAM) software package for Microsoft Office
Excel (22) for statistical analysis to identify genes
that were significantly differentially expressed. We
strategically fitted the multi-class algorithms of
SAM with data from the three groups. We found
that the exposed profiles were very similar to that
of the controls; the differences among the three
Table 2. Clinical and medical data for Stanley Medical Research Institute (SMRI) brains
ID # Diagnosis Mood stabilizer Antidepressants Anticholinergic Microarray note
5 BD Carbamazepine, lithium Trazodone —
14 BD Valproate Venlafaxine —
17 BD — Trazodone Diphenhydramine
45 BD Valproate,
carbamazepine
Sertraline — Not processed
47 BD Lithium — —
51 BD Lithium Buproprion —
55 BD Valproate — Benztropine
57 BD — — Diphenhydramine
4 BD — — —
7 BD — — —
8 BD — — —
24 BD Lithium — —
36 BD Valproate Bupropion,
fluoxetine
—
53 BD Carbamazepine, lithium Fluoxetine —
54 BD Valproate Clomipiramine —
2 CON — — —
3 CON — — — Not processed
6 CON — — —
9 CON — — —
15 CON — — —
27 CON — — —
31 CON — — —
35 CON — — —
41 CON — — — Quality control failed
46 CON — — —
49 CON — — —
50 CON — — —
56 CON — — —
58 CON — — — Not processed
59 CON — — —
BD = bipolar disorder; CON = control; ID # = SMRI-assigned patient number.
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groups were mostly contributed by the non-
exposed group. We therefore performed a SAM
two-class analysis between the non-exposed and
other profiles (exposed plus controls) to identify
and report differentially expressed genes.
The transcript sequences in National Center for
Biotechnology Information (NCBI) UniGene,
dbEST, GenBank, and Refseq databases were used
to design the U133p2 GeneChip. The current
annotation of these sequences is incomplete. We
therefore only focused on the analysis of probe sets
with NCBIs Refseq annotation.
We used SAM q-values [equivalent to false
discovery rate (FDR)] of 0.005 as cut-off points to
call significant genes. Since the correlation be-
tween fold change (FC) and functional impact
empirically remains unknown, we did not apply
an FC cut-off point to exclude any significant
calls.
Real-time quantitative reverse transcriptase–polymerase
chain reaction (qRT-PCR) validation of microarray results
Verification of microarray results was performed
with TaqMan qRT-PCR (23) using a 7900HT
Sequence Detection System (Applied Biosystems,
Foster City, CA, USA). Two micrograms of total
RNA from each sample was converted to first-
strand cDNA using the Superscript first-strand
cDNA synthesis system following the manufac-
turers instructions (Invitrogen, Cat #18089-011;
Carlsbad, CA, USA). The cDNA stocks were then
diluted 50-fold with distilled deionized water.
TaqMan assays were performed in 20-lL reactions
in 384-well format plates, each containing 10 lL of
2 · TaqMan Master Mixture, 1 lL of 20 · prim-
ers ⁄probe, and 9 lL of 50-fold diluted first-strand
cDNA templates. The ribosomal protein S16
(RPS16) gene which did not exhibit significant
variation in expression between samples was used
as an endogenous control. The Assays on Demand
(AOD) for seven brain-expressed genes were pur-
chased from Applied Biosystems (Foster City, CA,
USA). We used the 2)DDCt method (24) to calculate
FC using the threshold cycle value (Ct) in the
samples of non-exposed brains and controls after
normalizing to the Ct values of the internal
reference RPS16. For significance testing, two-
tailed t-tests were employed.
Gene ontology (GO) term enrichment analysis
We used the stand-alone expression analysis
systematic explorer (EASE) software for GO term
enrichment and pathway analysis (25). We used the
NCBIs Refseq genes as the background list. The
2022 unique genes (excluding 169 pH-related
transcripts) from the significant list were used as
input against the background genes for EASE to
identify genes specifically enriched in the GO
biological process system, molecular function sys-
tem, or Kyoto Encyclopedia of Genes and
Genomes (KEGG) pathways (26). Significantly
enriched GO terms were those with a Bonferroni p
of £0.05.
Results
Differential gene expression in brains from individuals with
BD compared with controls
A large number of genes were differentially
expressed in non-exposed brains. Using the SAM
multi-class algorithm (22), we identified 3376
gene transcripts differentially expressed between
the non-exposed, exposed, and control groups
(q-value £ 0.05, equivalent to FDR). At a
q-value £ 0.01 cut-off, 1184 unique genes repre-
sented by 1419 probe sets were differentially
expressed among the three groups (see Supplemen-
tary Fig. 1). We observed that the expression levels
of these significant transcripts in the exposed
brains were very similar to those of controls; the
significant differences were largely contributed by
the non-exposed group (see Supplementary Fig. 1).
This observation suggests that antipsychotics have
considerable effects on gene expression, and that
they appear to normalize the differentially
expressed genes in BD brains to the mean levels
of controls.
Since the exposed profiles were very similar to,
and highly correlated with, those of controls (see
Supplementary Fig. 1), we combined those groups
and then compared them with the non-exposed
group using the SAM two-class algorithms. We
identified 2191 unique transcripts (2818 probe sets)
differentially expressed in the non-exposed brains
(q £ 0.005) (Fig. 1). Among these 2191 transcripts,
116 showed an increase and 2075 a decrease in
mean abundance level in the non-exposed group
relative to the combined group (see Supplementary
Table 2). There was high concordance between the
multi-class and two-class analyses, with only
1.96% of the 2191 significant genes not identified
by SAM multi-class analysis (data not shown). The
two-class analysis achieved a much lower q-value
(£0.005) for the 2191 significant genes.
We also observed that most of the 2191 signif-
icant genes identified showed modest mean expres-
sion level changes (<2-fold). This is consistent
with published data (see Supplementary Table 1).
The minimum exposed versus control FC was
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)1.09-fold, and the maximum was )4.5-fold. We
also identified multiple significant transcript
variants from the same gene detected by corre-
sponding probe sets (see Supplementary Table 2).
Antipsychotic treatment normalizes gene expression in BD
brains
We found that the mean levels of the significant
transcripts were similar between the exposed brains
and controls (see Supplementary Fig. 1). For
instance, in the non-exposed brains the mean
abundance of regulator of G protein signaling 4
(RGS4), BCL 2 associated athanogene 3 (BAG3),
and synapsin 2 (SYN2) transcripts showed greater
than 2-fold change compared to that of the
combined samples, but there was no significant
difference between the exposed group and controls
(Fig. 2). This is of potential relevance as RGS4,
BAG3, and SYN2 have been implicated in psychi-
atric illnesses (27, 28) and in changes in the central
nervous system in response to antipsychotic treat-
ment (29–31).
Real-time qRT-PCR validation
Real-time qRT-PCR was employed to validate
seven randomly selected significant genes using
cDNAs derived from total RNA extracted from
the non-exposed brains and controls. The Taq-
Man results confirmed our microarray findings
for all seven genes (Table 3). The changes were
not correlated with age, gender, brain pH, or
PMI.
Gene ontology term enrichment analysis revealed
functional themes
EASE analysis excluded 169 unique genes known
to be related to low brain pH (10, 15, 32). There
was significant enrichment of genes in one KEGG
pathway, as well as 18 biological process terms and
11 terms of molecular function (Bonferroni
p £ 0.05) (see Supplementary Table 3). Significant
GO terms of biological processes presented a
theme of protein metabolic process, transport,
localization, post-translational protein modifica-
tion, protein folding, and synaptic transmission.
Significant GO terms of molecular function iden-
tified protein and nucleotide categories including
ATP binding, ligase, and catalytic activities. Inter-
estingly, long-term potentiation was the one sig-
nificant KEGG pathway identified in this analysis.
We found that multiple members of gene fam-
ilies were often enriched under corresponding GO
terms. For example, 13 genes encoding multiple
subunits of adaptor-related protein (AP) com-
plexes (AP1M1, AP1S1, AP1S2, AP2A1, AP2A2,
AP2B1, AP2M1, AP2S1, AP3B2, AP3M2, AP4B1,
AP4M1, and AP4S1) were enriched under the term
intracellular transport; and six genes encoding
eukaryotic translation initiation factors (EIF2B3,
EIF2B5, EIF2S1, EIF4E, EIF4G2, and EIF5) were
enriched under the GO term protein metabolic
process. Although no direct evidence relates any of
the AP subunits to BD, AP complexes are critical
proteins in synaptic vesicle formation and trans-
port (33). Multiple BD risk factors have been
proposed to interrupt protein synthesis via the
translation initiation complex EIF2B (34). Our
data implicate the functionally related genes
encoding proteins involved in neurotransmitter
biosynthesis, or protein synthesis and modification;
however, postmortem data such as these cannot
determine if there are causal or consequential
relationships between disease, pharmacological
intervention, and observed gene expression
changes. This will require cellular models that
can be studied prospectively.
Discussion
We examined the gene expression profiles of a
postmortem brain sample well matched by gender,
Fig. 1. Scatter plot illustrating the mean difference in log2 ratio
(M) versus the average expression level in log2 average (A) for
each of the genes analyzed. The yellow line indicates no dif-
ference in mean expression levels. A 2-fold mean difference
(log2 ratio) is indicated by a red line (up-regulated) or a green
line (down-regulated). The points shown in red or green are the




age, PMI, pH, side of the brain, and race (18). We
identified 2191 unique genes (FDR £ 0.005) differ-
entially expressed in the premotor cortex of indi-
viduals with BD who were not exposed to
antipsychotics at the time of death or during their
lifetime compared to exposed brains and controls.
We observed that in exposed brains the expression
levels of these genes were similar to those of
controls. This suggests that antipsychotics may
normalize (or at least suppress differences in) the
expression levels of several genes relevant to the
molecular pathophysiology of BD. This broad
effect on gene expression of the antipsychotics may
be one of several factors influencing the heteroge-
neity of the illness.
The normalization effect of antipsychotics is
supported by a recent report using induced
pluripotent stem cell (iPSC)-derived neurons to
model schizophrenia (35). This study identified
signaling pathways that were abnormal in cells
derived from individuals with schizophrenia, which
could be ameliorated by treatment with a typical
antipsychotic medication, loxapine (35). While the
outcome of gene expression modulation through
antipsychotic medication is common to the current
study and an iPSC-derived model of schizophrenia,
Fig. 2. A boxplot showing three messenger RNA (mRNA) species encoding BCL 2 associated athanogene 3 (BAG3), regulator of G
protein signaling 4 (RGS4), and synapsin 2 (SYN2) which were differentially expressed between exposed samples, controls, and non-
exposed samples. Shown on the y-axis are the measured expression levels of the genes, given as log2 values, and on the x-axis are the
three groups of brain samples.
Table 3. TaqMan analysis of differential gene expression between non-exposed brains and controls
TaqMan assay Microarray
Gene symbol t-test Fold changea Internal control gene SAM q-value Fold change
FKBP5 1.23E-03 1.88 RPS16 £0.005 1.88
BAG3 9.90E-03 2.50 RPS16 £0.005 2.52
ALDH1L1 5.72E-04 1.70 RPS16 £0.005 1.72
CALM1 6.80E-04 )1.80 RPS16 £0.005 )1.80
DUSP3 8.96E-04 )1.60 RPS16 £0.005 )1.70
SYN2 1.21E-04 )3.10 RPS16 £0.005 )3.05
KCNK1 8.47E-04 )1.92 RPS16 £0.005 )1.96
ALDH1L1 = aldehyde dehydrogenase 1 family, member L1; BAG3 = BCL 2 associated athanogene 3; CALM1 = calmodulin 1; DUSP3 =
dual specificity protein phosphatase 3; FKBP5 = FK506 binding protein 5; KCNK1 = potassium channel subfamily K member 1; SAM =
Significant Analysis of Microarrays; SYN2 = synapsin 2.
aTaqMan fold changes are derived from 2 ()DDCt),)DDCt = (mean exposed DCt ) mean control DCt).
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there are clearly many confounds from the envi-
ronment that affect the adult postmortem brain.
Medication is one of many tools to alter the
environment at defined stages, the results of which
may have causal relevance to either the illness or
the neuropharmacology of the medication.
Using their method of convergent functional
genomics, Le-Niculescu and colleagues (36) gener-
ated a list of 1529 genes implicated in BD or
depression. In a study of genomic variation for
schizophrenia, Lee and colleagues (37) reported
2725 genes containing common single nucleotide
polymorphisms (SNPs) that captured a significant
proportion of the variance in liability to schizo-
phrenia. In other common conditions, many genes
are implicated: for example, thousands of genes
were found to change expression levels in response
to viral infection in peripheral blood mononuclear
cells using integrative personal omics profiling
(38).
When our significant genes were compared with
the 375 significant genes identified in the meta-
analysis of 12 microarray data sets (17), 185 genes
were found to be common to both lists (Fishers
exact test p £ 0.015), and 99% of these common
changes were in the same direction (mostly down-
regulated) (see Supplementary Table 4). The
significant overlap suggests high concordance
between this current study and the meta-analysis.
It also implies that there may be common aspects
of pathophysiology in some brain regions, since the
current study was performed on tissue from the
BA6 region, while the meta-analysis (17) combined
profiles from different brain regions (mainly BA6,
9, 10, and 46) from 12 studies, including our
microarray raw data.
A recent microarray analysis of the thalamic
transcriptome performed on material from the
SMRI neuropathology consortium identified 72
genes with highly significantly altered expression
levels in bipolar brains (15). Of these, we found
that 22 genes were common to our study (Fishers
exact test p = 2.14 · 10)6) and all common
changes were in the same directions (two increased
and 20 decreased) (see Supplementary Table 5).
This comparison is reasonably sound since both
experiments were performed on the U133P2 Gene-
chips and tested similar numbers of probe sets
(around 22000).
It remains a challenge to identify causative
alterations in gene expression using microarray
data from postmortem tissues. We observed 86
genes that showed a 2-fold or greater difference in
mean expression levels between BD brains and the
combined group; for example, RGS4, BAG3, and
SYN2 showed 2-fold or greater changes (see
Fig. 2). RGS4 (regulator of G protein signaling 4)
has been associated with schizophrenia (39) and
implicated in BD (40). Though BAG3 has not been
previously implicated in BD, it has been identified
with relevant expression changes in response to
antipsychotic treatment in animal brains (29).
SYN2, a gene involved in synaptic function, has
been associated with BD in a functional analysis of
extant data (41). Given the assumption that larger
FCs have a greater functional impact, priority may
be given to the genes with higher magnitude
changes for further detailed analysis.
Functional GO term enrichment analysis identi-
fied significant clusters of genes under several
biological process terms, including protein meta-
bolic process, protein transport, macromolecule
localization, protein localization, intracellular pro-
tein transport, establishment of protein localiza-
tion, post-translational protein modification,
protein folding, molecular function, vesicle-medi-
ated transport, synaptic transmission, and intra-
cellular transport; or GO terms of molecular
function relating to protein binding, nucleo-
tide ⁄ ribonucleotide ATP binding, ligase and cata-
lytic activities. These data and neuropathological
studies of BD brains suggest that, as in neurode-
generative conditions, protein processing and
transport may be significantly altered.
The enriched genes under specific GO terms
often included multiple members of gene families.
For example, five members of the disintegrin and
metalloprotease (ADAM) gene family, ADAM10,
ADAM11, ADAM15, ADAM17, and ADAM23,
were in enriched under the GO term protein
metabolic process. The ADAM genes encode
membrane-anchored proteins that have been
shown to play important roles in the development
of the nervous system, including regulation of the
proliferation, migration, differentiation and sur-
vival of various cells, as well as axonal growth
and myelination (42). Enriched under the GO
term protein transport were 13 members of adap-
tor-related protein complex (AP) gene families:
AP1M1, AP1S1, AP1S2, AP2A1, AP2A2, AP2B1,
AP2M1, AP2S1, AP3B2, AP3M2, AP4B1, AP4M1,
and AP4S1. AP complexes, AP-1, AP-2, AP-3, and
AP-4, play important roles in synaptic vesicle
formation and endocytosis (33). The expression
levels of these genes were significantly lower in
non-exposed brains compared to controls, suggest-
ing a hypothesis of synapse impairment in BD.
How these genes may be involved in BD is
currently unknown, and awaits analysis in relevant
cellular models.
A number of high profile genes previously
implicated in BD also stand out in our study. For
Chen et al.
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example, the mRNA levels of the glycogen
synthase kinase 3 beta (GSK3B), FK506 binding
protein 5 (FKBP5), and Ankyrin 3 (ANK3) genes
were altered in the non-antipsychotic medication
brains. GSK3b is a known target of lithium, and
has been hypothesized to be the molecular basis of
lithium treatment of BD (43). FK506 binding
protein 51, the protein product of the FKBP5 gene,
forms part of a complex with the glucocorticoid
receptor and can modulate cortisol-binding affinity
(44). Variations in FKBP5 have been reported to
be associated with BD (45).
The ANK3 gene product, Ankyrin-G, is present
at the axonal initial segment and at nodes of
Ranvier. Ankyrin-G plays key roles in node
formation and function in the central and periph-
eral nervous systems. Genome-wide association
analysis identified SNPs at the ANK3 locus asso-
ciated with BD (46), and cis-acting variations in the
ANK3 locus were shown to affect its expression
(47). In addition to ANK3, several genes encoding
key components of the node of Ranvier or paran-
odal region, such as neuronal cell adhesion
molecule (NRCAM), sodium channel, voltage
gated type 8 alpha (SCN8A), potassium voltage-
gated channel 2 (KCNQ2), spectrin, beta, non-
erythrocytic 4 (SPTBN4), erythrocyte membrane
protein 4.1-like 3 (EPB41L3), and ANK2, are
among the list of genes identified in this study
(see Supplementary Table 2). These observations
suggest node impairment may be a neural mech-
anism of BD.
The limitations of the current analysis relate
primarily to the relatively small number of individ-
uals included in the study of postmortem samples. It
would be useful to replicate these findings in
additional samples and studies; however, there is
considerable overlap in the genes identified in the
current study with those from previous studies (15,
17). There are many confounding factors that
essentially limit the utility of postmortem gene
expression analyses, which include sex-dependent
expression differences, death and agonal factors
including the PMI and tissue pH. The postmortem
brainmost likely reflects the end-stage organ disease
state and may not reflect the initial etiological
mechanisms of the disorder. There are several
options for improving the study design and include:
(i) the ascertainment and procurement of additional
postmortem brains for study and (ii) the establish-
ment of cellular models that are derived from
individuals with BD for whom there are consider-
able phenotypic and longitudinal data that may be
factored into the analyses. Clearly, the second
option is the ideal option. Individuals with BD
who have common phenotypic features may be
ascertained and sampled, their cell lines grown
under controlled conditions of exposure to envi-
ronmental perturbations (medications and other
biological variations) and measured consistently.
Cellular models range from iPSC-derived neurons
to cells derived from B lymphocytes transformed
with Epstein Barr Virus (EBV), the consistent
feature being cellular tissue derived from an
individual with the disorder. The limitations of the
cellular models are the lack of ability to study the
complex circuitry of the human brain; however,
complex biochemical pathways could be studied at
a sophisticated biological level to determine inter-
active correlates between pathways.
In summary, we identified a large number of
genes with altered expression in brains from
individuals with BD who had not been exposed
to antipsychotics. In brains of individuals with BD
treated with antipsychotics, expression of these
genes was normalized to the levels found in healthy
controls. Functional GO terms analysis suggests
that these gene products are involved in neuronal
communication that may be impaired in BD
brains. Although our current results are concor-
dant with previous findings, caution must be
exercised in interpreting data generated from
postmortem brains that are further confounded
by agonal status, tissue pH, PMI, medication, etc.
Neuropsychiatric and neurological diseases are
increasingly thought to be developmental in
nature, and the fact that disease-specific changes
are unlikely to be distinguished from confounders
in postmortem brains suggests that disease-specific
live neurons are critically required to study the
molecular basis of BD and to assemble a palette of
disease-causing genes. This goal will be achieved in
the systematic study of live neurons derived from
iPSCs (48) or from differentiated easily accessible
tissue of non-neural origin (35, 49).
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